Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Increase in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 141,200 shares, a growth of 27.7% from the December 15th total of 110,600 shares. Based on an average trading volume of 95,500 shares, the short-interest ratio is currently 1.5 days. Currently, 0.7% of the company’s shares are sold short.

Aileron Therapeutics Stock Performance

Aileron Therapeutics has a 1-year low of $1.61 and a 1-year high of $7.42. The firm has a market capitalization of $45.72 million, a PE ratio of -0.68 and a beta of 2.24. The firm’s 50-day moving average price is $2.52 and its 200 day moving average price is $2.80.

Hedge Funds Weigh In On Aileron Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. KG&L Capital Management LLC bought a new stake in shares of Aileron Therapeutics in the 3rd quarter valued at $46,000. Sigma Planning Corp grew its stake in Aileron Therapeutics by 68.3% in the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after acquiring an additional 86,185 shares during the period. Geode Capital Management LLC increased its holdings in shares of Aileron Therapeutics by 34.8% in the third quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after acquiring an additional 59,370 shares in the last quarter. Nantahala Capital Management LLC raised its position in shares of Aileron Therapeutics by 82.1% during the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Aileron Therapeutics during the second quarter worth about $4,925,000. 90.89% of the stock is owned by institutional investors.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).